stockrow
Monday 9 November 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMPCAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024.
- Revenue
- +138.9%
- EPS
- +32.7%
- Free cash flow
- +20.4%
Quarter to September 2026, against a year earlier
4.06
0.34
+9.14%
Follow CAMP
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
94.52 | 64.93 | 60.05 | 59.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
52.54 | (23.26) | (19.96) | (39.06) | |
P/B ratio |
6.93 | 8.27 | 0.00 | 2.98 | |
Price to Tangible BV |
6.93 | 8.27 | 0.00 | 2.98 | |
EV/Sales |
62.84 | 39.54 | 39.39 | 36.42 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.44) | (5.93) | (5.81) | (7.59) | |
EV/FCF |
(7.38) | (5.87) | (5.79) | (7.35) | |
Quick Ratio |
7.15 | 6.01 | 4.55 | 6.31 | |
Current Ratio |
7.35 | 6.15 | 4.70 | 6.42 | |
Net Debt/EBITDA |
8.94 | 7.96 | 6.77 | 9.27 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.04 | 0.05 | 0.06 | 0.05 | |
Operating CF/Net income |
(0.16) | 0.60 | 0.38 | 0.28 | |
Capex/Depreciation |
0.00 | 0.00 | (0.25) | (1.41) | |
Research and Development Expense of Revenue |
2,401.44% | 785.16% | 608.04% | 602.11% | |
Selling, General and Administrative Expense of Revenue |
1,369.83% | 324.96% | 244.07% | 236.65% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
330.75% | 113.76% | 108.54% | 106.58% | |
Graham Net Nets |
0.13 | 0.11 | (0.02) | 0.32 | |
Graham Number |
0.00 | 0.00 | 0.77 | 0.00 | |
Earnings Yield |
(41.38%) | (50.72%) | (50.27%) | (49.92%) | |
Free Cash Flow Yield |
(9.01%) | (10.37%) | (11.33%) | (8.27%) | |
Revenue per Share |
0.01 | 0.02 | 0.03 | 0.02 | |
Operating CF per Share |
0.12 | (0.19) | (0.22) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.12 | (0.19) | (0.22) | (0.11) | |
Cash per Share |
2.06 | 1.73 | 1.50 | 1.59 | |
Shareholders Equity per Share |
0.88 | 0.53 | (0.01) | 1.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.88 | 0.53 | (0.01) | 1.36 | |
Free Cash Flow |
6.29 | (10.98) | (12.81) | (8.90) | |
Working Capital |
98.58 | 85.57 | 70.89 | 107.67 | |
Capital Expenditures |
0.00 | — | (0.13) | (0.74) | |
Net Current Asset Value |
43.99 | 27.64 | (4.09) | 100.62 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.07 | 0.39 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.70 | 1.13 | 1.14 | 0.67 | |
Average Assets |
98.06 | 84.12 | 72.35 | 110.20 | |
Average Common Equity |
55.42 | 41.24 | 19.65 | 82.88 |
Columns are period end dates · fundamentals updated 5 Nov 2026